Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda B Spurdle

Showing results (151-160 of 398) with videos related to

Pageof 40
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab InvestigatorsAmanda B Spurdle, Sunil R Lakhani, Sue Healey, et al.
Human Mutation|October 13, 2011
ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genesAmanda B Spurdle, Sue Healey, Andrew Devereau, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancersAndrew Berchuck, Joellen M Schildkraut, Robert M Wenham, et al.
Human Mutation|August 27, 2005
A protein-truncating mutation in CYP17A1 in three sisters with early-onset breast cancerJohn L Hopper, Vanessa M Hayes, Amanda B Spurdle, et al.
Breast Cancer Research and Treatment|October 26, 2006
Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variabilityPaul K Lovelock, Ee Ming Wong, Carl N Sprung, et al.
Gynecologic Oncology|September 14, 2010
Vascular endothelial growth factor gene polymorphisms and ovarian cancer survivalFelicity Lose, Christina M Nagle, Tracy O'Mara, et al.
Human Mutation|March 12, 2011
Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundaryPhillip J Whiley, Lucia Guidugli, Logan C Walker, et al.
Human Mutation|July 30, 2013
Evaluation of a 5-tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data: inter-reviewer variability and promotion of minimum reporting guidelinesLogan C Walker, Phillip J Whiley, Claude Houdayer, et al.
Breast Cancer Research and Treatment|December 7, 2007
The RAD51D E233G variant and breast cancer risk: population-based and clinic-based family studies of Australian womenJames G Dowty, Felicity Lose, Mark A Jenkins, et al.
Clinical Epigenetics|July 10, 2020
The MLH1 polymorphism rs1800734 and risk of endometrial cancer with microsatellite instabilityHolly Russell, Katarzyna Kedzierska, Daniel D Buchanan, et al.
Pageof 40

Showing results (151-160 of 398) with videos related to

Sort By:
Pageof 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab InvestigatorsAmanda B Spurdle, Sunil R Lakhani, Sue Healey, et al.
Human Mutation|October 13, 2011
ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genesAmanda B Spurdle, Sue Healey, Andrew Devereau, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancersAndrew Berchuck, Joellen M Schildkraut, Robert M Wenham, et al.
Human Mutation|August 27, 2005
A protein-truncating mutation in CYP17A1 in three sisters with early-onset breast cancerJohn L Hopper, Vanessa M Hayes, Amanda B Spurdle, et al.
Breast Cancer Research and Treatment|October 26, 2006
Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variabilityPaul K Lovelock, Ee Ming Wong, Carl N Sprung, et al.
Gynecologic Oncology|September 14, 2010
Vascular endothelial growth factor gene polymorphisms and ovarian cancer survivalFelicity Lose, Christina M Nagle, Tracy O'Mara, et al.
Human Mutation|March 12, 2011
Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundaryPhillip J Whiley, Lucia Guidugli, Logan C Walker, et al.
Human Mutation|July 30, 2013
Evaluation of a 5-tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data: inter-reviewer variability and promotion of minimum reporting guidelinesLogan C Walker, Phillip J Whiley, Claude Houdayer, et al.
Breast Cancer Research and Treatment|December 7, 2007
The RAD51D E233G variant and breast cancer risk: population-based and clinic-based family studies of Australian womenJames G Dowty, Felicity Lose, Mark A Jenkins, et al.
Clinical Epigenetics|July 10, 2020
The MLH1 polymorphism rs1800734 and risk of endometrial cancer with microsatellite instabilityHolly Russell, Katarzyna Kedzierska, Daniel D Buchanan, et al.
Pageof 40